Research Papers:

Lipolysis-stimulated lipoprotein receptor overexpression is a novel predictor of poor clinical prognosis and a potential therapeutic target in gastric cancer

Takahito Sugase, Tsuyoshi Takahashi _, Satoshi Serada, Minoru Fujimoto, Tomoharu Ohkawara, Kosuke Hiramatsu, Masahiro Koh, Yurina Saito, Koji Tanaka, Yasuhiro Miyazaki, Tomoki Makino, Yukinori Kurokawa, Makoto Yamasaki, Kiyokazu Nakajima, Kazuhiro Hanazaki, Masaki Mori, Yuichiro Doki and Tetsuji Naka

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:32917-32928. https://doi.org/10.18632/oncotarget.25952

Metrics: PDF 594 views  |   HTML 904 views  |   ?  


Takahito Sugase1,2,3, Tsuyoshi Takahashi1, Satoshi Serada2, Minoru Fujimoto2, Tomoharu Ohkawara2, Kosuke Hiramatsu2, Masahiro Koh1, Yurina Saito1, Koji Tanaka1, Yasuhiro Miyazaki1, Tomoki Makino1, Yukinori Kurokawa1, Makoto Yamasaki1, Kiyokazu Nakajima1, Kazuhiro Hanazaki3, Masaki Mori1, Yuichiro Doki1 and Tetsuji Naka2

1Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Suita, Japan

2Center for Intractable Immune Disease, Kochi University, Nankoku, Japan

3Department of Surgery, Kochi University, Nankoku, Japan

Correspondence to:

Tsuyoshi Takahashi, email: ttakahashi2@gesurg.med.osaka-u.ac.jp

Tetsuji Naka, email: naka@kochi-u.ac.jp

Keywords: gastric cancer; LSR; lipid metabolism; antibody therapy; mouse model

Received: April 30, 2018     Accepted: July 28, 2018     Published: August 31, 2018


The prognosis of patients with advanced gastric cancer (GC) remains poor despite the recent advances in molecular targeted therapies, and the search for biomarkers that can predict prognosis and additional new agents with acceptable toxicity profiles are needed. Lipolysis-stimulated lipoprotein receptor (LSR) is a lipoprotein receptor that binds to triglyceride-rich lipoproteins and related to some malignancies. Herein, we examined the association between LSR expression and the prognosis of patients with GC, and investigated the antitumor effect of a previously developed anti-human LSR monoclonal antibody (#1–25). We first performed immunohistochemical analysis of LSR protein expression in GC and normal tissues, and then examined its association with the prognosis of 110 patients with GC. LSR was overexpressed in most of primary GC and metastatic tumors, but not in normal tissues. Patients with strong LSR expression (N = 80, 72.7%) had significantly poorer overall survival (OS) than those with weak expression (P = 0.017). Multivariate analysis identified strong LSR (as well as pT) as independent and significant prognostic factors for OS. Next, we demonstrated that very low density lipoprotein (VLDL) treatment increases cell proliferation in LSR-expressing GC cell lines in vitro; LSR inhibition using #1–25 inhibited VLDL-induced proliferation by suppressing JAK/STAT and PI3K signaling. In vivo, we demonstrated a marked antitumor effect of #1–25 in 2 distinct GC cell line xenograft mice models. Our findings suggest that LSR plays a key functional role in GC development, and that this antigen can be therapeutically targeted to improve GC treatment.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 25952